IRIS UniCatt

De Luca, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.718
EU - Europa 7.223
AS - Asia 5.985
SA - Sud America 1.436
AF - Africa 171
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
AN - Antartide 1
Totale 23.553
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.485
SG - Singapore 2.780
DE - Germania 1.920
CN - Cina 1.791
BR - Brasile 1.228
SE - Svezia 1.094
UA - Ucraina 906
FR - Francia 715
PL - Polonia 695
IT - Italia 539
IE - Irlanda 384
GB - Regno Unito 297
VN - Vietnam 294
ID - Indonesia 267
FI - Finlandia 238
IN - India 225
RU - Federazione Russa 178
TR - Turchia 113
CA - Canada 100
HK - Hong Kong 95
AR - Argentina 94
BD - Bangladesh 84
MX - Messico 65
JP - Giappone 64
IQ - Iraq 56
ZA - Sudafrica 55
AT - Austria 42
NL - Olanda 41
BE - Belgio 37
ES - Italia 30
EC - Ecuador 26
PK - Pakistan 26
IR - Iran 25
CO - Colombia 20
KE - Kenya 19
MA - Marocco 19
VE - Venezuela 18
UZ - Uzbekistan 16
CL - Cile 15
EG - Egitto 15
LT - Lituania 15
AE - Emirati Arabi Uniti 14
KR - Corea 14
JO - Giordania 13
PY - Paraguay 13
HN - Honduras 12
PE - Perù 12
BZ - Belize 11
CH - Svizzera 11
JM - Giamaica 11
SA - Arabia Saudita 11
TN - Tunisia 11
AZ - Azerbaigian 9
BG - Bulgaria 9
IL - Israele 9
RO - Romania 9
CI - Costa d'Avorio 8
CM - Camerun 8
DZ - Algeria 8
GT - Guatemala 8
NP - Nepal 8
PH - Filippine 8
EU - Europa 7
GR - Grecia 7
KZ - Kazakistan 7
CZ - Repubblica Ceca 6
OM - Oman 6
PA - Panama 6
TT - Trinidad e Tobago 6
BO - Bolivia 5
BY - Bielorussia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
HU - Ungheria 5
KG - Kirghizistan 5
LB - Libano 5
LU - Lussemburgo 5
NZ - Nuova Zelanda 5
AL - Albania 4
AO - Angola 4
AU - Australia 4
EE - Estonia 4
GE - Georgia 4
LK - Sri Lanka 4
NI - Nicaragua 4
PT - Portogallo 4
QA - Qatar 4
UY - Uruguay 4
LA - Repubblica Popolare Democratica del Laos 3
RS - Serbia 3
SN - Senegal 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CR - Costa Rica 2
GH - Ghana 2
Totale 23.504
Salva come PNG Salva come JPEG
Città #
Chandler 1.369
Singapore 1.065
Ashburn 793
Jacksonville 571
Kraków 520
San Mateo 406
Dublin 380
Beijing 353
New York 347
Dearborn 287
Nanjing 275
Jakarta 241
Wilmington 230
Houston 176
Ann Arbor 171
Warsaw 162
Lawrence 161
Boston 154
Cattolica 151
Redmond 143
Los Angeles 139
Hangzhou 138
Hefei 136
Woodbridge 132
Seattle 109
Moscow 107
Dallas 106
Nürnberg 106
Ho Chi Minh City 103
Nanchang 102
Milan 99
Redwood City 91
Hong Kong 88
São Paulo 87
Izmir 80
Princeton 75
Lancaster 74
Boardman 70
Frankfurt am Main 70
Hanoi 69
Mountain View 67
University Park 64
Shenyang 58
Munich 57
Buffalo 55
Fairfield 54
Kunming 48
Chicago 47
Guangzhou 46
Rio de Janeiro 44
Tokyo 44
Bremen 43
Hebei 43
Norwalk 43
Rome 42
Changsha 40
Brussels 36
Atlanta 35
Kent 35
Fremont 34
Jiaxing 34
Marseille 34
Johannesburg 33
London 32
San Jose 31
Ottawa 30
Philadelphia 30
Pune 30
Santa Clara 30
Tianjin 30
Belo Horizonte 29
Falls Church 28
Jinan 28
Shanghai 27
Nuremberg 26
Cambridge 25
Verona 25
Brasília 23
Helsinki 23
The Dalles 23
Düsseldorf 22
Montreal 22
Zhengzhou 22
Leawood 21
San Francisco 21
Vienna 21
Scottsdale 19
Simi Valley 19
Toronto 19
Amsterdam 18
Brooklyn 18
Curitiba 18
Washington 18
Mexico City 17
Paris 17
Porto Alegre 17
Stockholm 17
Augusta 16
Da Nang 15
Lauterbourg 15
Totale 11.814
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 358
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 315
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 253
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 249
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 236
Common genetic variation and the control of HIV-1 in humans. 235
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 212
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 199
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 191
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 188
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 179
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 170
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 170
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 164
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 162
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 161
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 158
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 155
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 154
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 154
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 150
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 149
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 144
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 144
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 143
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 142
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 142
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 142
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 140
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 139
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 139
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 138
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 137
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 137
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 136
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 136
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 136
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120 135
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 134
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 134
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 133
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 133
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 132
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 131
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 131
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 130
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 128
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 127
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 127
Phemphigus vulgaris in a human-immunodeficiency-virus-infected patient. 127
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 127
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 126
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 124
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 123
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 123
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 123
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 122
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 121
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 120
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 118
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 118
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 118
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study 117
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 117
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 117
Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients 116
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 116
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 116
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). 115
Lipid-lowering effect of tenofovir in HIV-infected patients 115
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 115
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 115
Long term follow-up of Nevirapine-treated patients in a single centre cohort 113
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 113
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 113
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 112
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 111
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 110
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 109
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 109
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 108
A novel methodology for large-scale phylogeny partition 108
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 108
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 108
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 108
Determinants of survival in progressive multifocal leucoencephalopathy 106
Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 106
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 106
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. 105
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 105
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 105
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 105
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 105
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 104
Italian consensus statement on management of HIV-infected individualswith advanced disease naive to antiretroviral therapy 104
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases 103
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 103
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 103
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 103
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 103
Totale 13.777
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.730
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021950 0 0 0 0 0 99 191 31 272 38 280 39
2021/20221.870 185 198 43 94 68 81 31 315 70 137 260 388
2022/20233.527 475 477 286 502 307 453 82 297 448 36 106 58
2023/20241.724 73 554 31 136 51 379 79 34 18 28 190 151
2024/20253.232 83 101 269 76 277 131 101 207 568 269 578 572
2025/20264.971 1.462 271 576 1.026 1.526 110 0 0 0 0 0 0
Totale 23.743